^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-06940434

    i
    Other names: PF-06940434, PF06940434, PF 06940434
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    αVβ8 integrin inhibitor
    Related drugs:
    Associations

    News

    Trials
    21d
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=85, Active, not recruiting, Pfizer | Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    sasanlimab (PF-06801591) • PF-06940434
    1year
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=195 --> 75 | Trial completion date: Oct 2025 --> Jul 2024 | Trial primary completion date: Oct 2025 --> Jul 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    sasanlimab (PF-06801591) • PF-06940434
    over1year
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=195, Recruiting, Pfizer | N=104 --> 195
    Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    sasanlimab (PF-06801591) • PF-06940434
    over1year
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=104, Recruiting, Pfizer | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2025 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    sasanlimab (PF-06801591) • PF-06940434
    over1year
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=104, Recruiting, Pfizer | Trial completion date: Nov 2023 --> Feb 2025 | Trial primary completion date: Nov 2023 --> Feb 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    sasanlimab (PF-06801591) • PF-06940434
    almost2years
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=104, Recruiting, Pfizer | Active, not recruiting --> Recruiting | N=69 --> 104 | Trial completion date: Aug 2023 --> Nov 2023 | Trial primary completion date: Aug 2023 --> Nov 2023
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    sasanlimab (PF-06801591) • PF-06940434
    almost2years
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=69, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=122 --> 69
    Enrollment closed • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    sasanlimab (PF-06801591) • PF-06940434
    almost3years
    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=104, Recruiting, Pfizer | Trial completion date: Jan 2024 --> Jun 2023 | Trial primary completion date: Jan 2024 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    PD-1 (Programmed cell death 1)
    |
    sasanlimab (PF-06801591) • PF-06940434